medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2003, Number 3

<< Back Next >>

Ann Hepatol 2003; 2 (3)

Current therapies for chronic hepatitis B

Buti M

Language: English
References: 37
Page: 108-112
PDF size: 46.83 Kb.


Text Extraction

Introduction

Chronic hepatitis B is a major public health problem and there are an estimated 400 million people worldwide infected with the Hepatitis B virus (HBV). It is one of the most common causes of hepatic cirrhosis and hepatocarcinoma. The prevalence of chronic hepatitis B varies in different geographic locations. In the Western countries, hepatitis B is the third most common cause of chronic liver disease after hepatitis C and alcohol.


REFERENCES

  1. Mast EE, Alter MJ. Epidemiology of viral hepatitis: an overview. Sem Virol 1993: 4: 273-283.

  2. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.

  3. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. New Engl J Med 1997; 336: 347-356.

  4. Rosenberg PM, Dienstag JL. Therapy with nucleoside analogues for hepatitis B virus infection. Clinics Liver Dis 1999; 3: 349-360.

  5. Lok AS, Heatchote EJ, Hoofnagle JH. Management of hepatitis B: summary of a workshop. Gastroenterology 2001; 120: 1828-1853.

  6. Balfour HHJ. Antiviral drugs. N Engl J Med 1999; 340: 1255-1268.

  7. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-68.

  8. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082-1087.

  9. Dienstag JL, Schiff ER, Wight TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-1263.

  10. Schiff E, Karayalcin S, Grimm I, et al. A placebo controlled study of lamivudine and interferon alpha-2b in patients with chronic hepatitis B who previously failed interferon therapy. Hepatology 1998; 28(4)Part 2: 388a.

  11. Chien RN, Liaw YF, Atkins M, et al. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770-774.

  12. Liaw YF, Lai CL, Leung NWY, et al. Two years lamivudine therapy in chronic hepatitis B infection: results of a placebo-controlled multicenter study in Asia. Gastroenterology 1998; 114(4 Pt. 2): A1289.

  13. Liaw Y-F, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 172-80.

  14. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889-896.

  15. Tassopoulos NC, Volpes R, Pastore G, et al. Post lamivudine treatment follow up of patients with HBeAg negative chronic hepatitis B J Hepatol 1999; 30 (Suppl. 1): 117.

  16. Allen MI, Deslauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 1670-1677.

  17. Stuyver LJ, Locarnini S A, Lok A, et al. Nomenclature for antiviral-resistant human Hepatitis B virs mutations in the polymerase region. Hepatology 2001; 33: 751-757.

  18. Zoulim F, Trepo C. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J Hepatol 1999; 29: 51-168.

  19. Leung NW, Lai CL, Guan R, et al. The effect of longer duration of harboring lamivudine-resistant hepatitis Virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001; 34; 348 A.1999; 30: 567-572.

  20. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567-572.

  21. Perrillo RP, Schiff ER, Dienstag JL, et al. Lamivudine for suppression of viral replication in patients with decompensated chronic hepatitis B. Hepatology 1999; 28(4 Pt. 2): 301A.

  22. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantion. Transplantion 1996; 62: 1456-1462.

  23. Aye TT, Bartholomeusz A, Shaw T, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997; 26: 1148-1153.

  24. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581-1586.

  25. Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States—Canadian trial assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424-432.

  26. Shaw T, Locarnini S. Combination chemotherapy for hepatitis B virus: The final solutions? Hepatology 2000; 32: 430-432.

  27. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Siffman M, et al. Adefovir dipivoxil for the treatment of patients Hepatitis B e Antigen positive chronic hepatitis B. New Engl J Med 2003; 348: 808-816.

  28. Hadziyannis S, Tassopoulos N, Heatchote J, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of patients Hepatitis B e Antigen negative chronic hepatitis B. New Engl J Med 2003; 348: 800-807.

  29. Perillo R, Schiff E, Hann H-WL, Buti M, Strasser S, Watkins KM, et al. The addition of adefovir dipivoxyl to lamivudine in decompensated chronic hepatitis B patients with YMDD variant HBV and reduced response to lamivudine, preliminary 24 weeks results. Hepatology 2001; 34: 349A.

  30. Westland CE, Yang H, Namini H, Lama N, Gibbs CS, Miller MD, et al. Comparison of anti-HBV activity and adefovir against different lamivudine-resistant HBV strains in vitro and in liver transplant patients. Hepatology 2001; 34: 446A.

  31. Peters M, Hann HW, Martin P, Heathcote E, Buggisch P, Moorat AE, et al. Adefovir dipivoxil alone and in combination with lamivudine suppresses YMDD mutant Hepatitis B virus replication: 48 week preliminary analysis. Hepatology 2002; 36: 374A.

  32. Schiff E, Lai CL, Nehaus P, Tillman H, Samuel D, Villanueve J-P, et al. Adefovir dipivoxil for the treatment of chronic hepatitis B in patients pre and post-Liver transplantation with lamivudine-resistant Hepatitis B virus patients. Hepatology 2002; 36: 371A.

  33. Westland C, Gibbs C, Miller M, Sullivan M, Fry J, Brosgart C, et al. Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy. J Hepatol 2002; 36 (Suppl 1): 7.

  34. Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T, Gutfreund K, et al. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129-134.

  35. Yang H, Westland C, Delaney WE, Heatchote E, Ho V, Fry J, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir for up to 60 weeks. Hepatology 2002; 36: 464-473.

  36. Heatchote E, Jeffers L, Perrillo R, Wright T, Sherman M, Namini H, et al. Sustained antiviral response and lack of resistance with long-term adefovir dipivoxil therapy in chronic HBV infection. J Hepatol 2002; 36 (Suppl 1): 110-1.

  37. Locarnini SA. Hepatitis B virus surface antigen and polymerase gene variants: potential virological and clinical significance. Hepatology 1998; 27: 294-7.




2020     |     www.medigraphic.com